NEWS
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
OKYO Pharma is set to begin a Phase 2 clinical trial of OK-101 for treating neuropathic corneal pain (NCP) in Q3 2024. This is the first instance of an FDA IND clearance for a drug targeting NCP, a significant unmet medical need. OK-101 has shown statistically significant pain relief in previous trials for dry eye disease and preclinical models of NCP. The 12-week, placebo-controlled trial will be led by Dr. Pedram Hamrah at Tufts Medical Center, involving 48 NCP patients. The study aims to measure pain improvement using a visual analogue scale (VAS).
CEO Dr. Gary S. Jacob emphasizes the potential of OK-101, highlighting its previous success in reducing pain in dry eye patients, some of whom suffer from NCP. The trial's design includes five study visits over 16 weeks, with pain improvement as the primary endpoint. Encouraging preclinical and clinical data support the trial's objectives. More details are available in the company's Form 6-K filing.
OKYO Pharma is set to begin a Phase 2 clinical trial of OK-101 for treating neuropathic corneal pain (NCP) in Q3 2024. This is the first instance of an FDA IND clearance for a drug targeting NCP, a significant unmet medical need. OK-101 has shown statistically significant pain relief in previous trials for dry eye disease and preclinical models of NCP. The 12-week, placebo-controlled trial will be led by Dr. Pedram Hamrah at Tufts Medical Center, involving 48 NCP patients. The study aims to measure pain improvement using a visual analogue scale (VAS).
CEO Dr. Gary S. Jacob emphasizes the potential of OK-101, highlighting its previous success in reducing pain in dry eye patients, some of whom suffer from NCP. The trial's design includes five study visits over 16 weeks, with pain improvement as the primary endpoint. Encouraging preclinical and clinical data support the trial's objectives. More details are available in the company's Form 6-K filing.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1164Followers
73Following
8109Visitors
Follow